SONN vs. CARM, BFRG, BTAI, PIRS, AFMD, MEIP, FNCH, BCTX, SNTI, and NKGN
Should you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Carisma Therapeutics (CARM), Bullfrog AI (BFRG), BioXcel Therapeutics (BTAI), Pieris Pharmaceuticals (PIRS), Affimed (AFMD), MEI Pharma (MEIP), Finch Therapeutics Group (FNCH), BriaCell Therapeutics (BCTX), Senti Biosciences (SNTI), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry.
Sonnet BioTherapeutics vs.
Sonnet BioTherapeutics (NASDAQ:SONN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
Sonnet BioTherapeutics has higher earnings, but lower revenue than Carisma Therapeutics.
Sonnet BioTherapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Sonnet BioTherapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. Sonnet BioTherapeutics' return on equity of -383.45% beat Carisma Therapeutics' return on equity.
Sonnet BioTherapeutics received 3 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. Likewise, 83.33% of users gave Sonnet BioTherapeutics an outperform vote while only 77.27% of users gave Carisma Therapeutics an outperform vote.
In the previous week, Sonnet BioTherapeutics had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Sonnet BioTherapeutics and 2 mentions for Carisma Therapeutics. Sonnet BioTherapeutics' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.
9.4% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Comparatively, 12.6% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Sonnet BioTherapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 1,198.70%. Carisma Therapeutics has a consensus price target of $4.94, suggesting a potential upside of 973.91%. Given Sonnet BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Carisma Therapeutics.
Summary
Sonnet BioTherapeutics beats Carisma Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Sonnet BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonnet BioTherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SONN) was last updated on 1/22/2025 by MarketBeat.com Staff
Free SONN Stock Alerts